Citation Impact
Citing Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
Extracellular vesicles and particles impact the systemic landscape of cancer
2022
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
2013 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
Reconstituted Immunity against Persistent Parvovirus B19 Infection in a Patient with Acquired Immunodeficiency Syndrome after Highly Active Antiretroviral Therapy
2001
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Hereditary Renal Cell Carcinoma Syndromes
2015
NOSOCOMIAL OUTBREAK OF PARVOVIRUS B19 INFECTION IN A RENAL TRANSPLANT UNIT12
2001
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Cancer stem cells revisited
2017 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Pre-metastatic Niche Formation in Different Organs Induced by Tumor Extracellular Vesicles
2021
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
2018
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
2017
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
New developments for antibody-drug conjugate-based therapeutic approaches
2016
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
2016
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
2018
Renal cell carcinoma
2017 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Parvovirus B19
2004 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
The “Utility” of Highly Toxic Marine-Sourced Compounds
2019
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
2017
Human Parvovirus B19
2002 Standout
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
2020
Bladder Cancer
2020 Standout
A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant
2013 StandoutNobel
Succinate dehydrogenase (SDH)‐deficient neoplasia
2017
Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
2013
Avelumab for the treatment of urothelial cancer
2018
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings
2007 Standout
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Improvement of Anemia Induced by Parvovirus B19 in a Patient With AIDS After Combined Antiretroviral Therapy
2000
Pixantrone–Rituximab Versus Gemcitabine–Rituximab In Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
2016
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Improvement of Anemia Induced by Parvovirus B19 in a Patient With AIDS After Combined Antiretroviral Therapy
2000
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
2018
Works of Anthony Mega being referenced
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL
2011
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling
2015
Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy
1999
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
2016
Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
2016
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
2017
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
2013
Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol‐dependent manner
2020
The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
2012
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
2012
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
2015